12.05.2017 • NewsagmDede WillamsLinde

Linde Leaders Face Criticism at AGM

(c) Linde Group
(c) Linde Group

At Linde’s annual general meeting in Munich on May 10, supervisory board chairman, Wolfgang Reitzle and interim CEO, Aldo Belloni, faced hefty criticism from shareholders’ representatives over the plan to merge with US rival Praxair, adding to the discontent already voiced by employee representatives.

Both groupings fear that the combination with the US player would diminish the standing the traditional German gases and engineering group enjoys. Employees also fear a massive loss of jobs, as Praxair, despite a leaner workforce reportedly produces higher profit margins.

All calls for a vote to block approval of the transaction dissipated, however. The meeting endorsed Reitzle with an acceptance rate of 94.47% and Belloni with 96.3%. Belloni said he hopes to finally clinch the deal with Praxair by the end of June. While it has been known for some time that the US company’s Steve Angel will head the merged gases giant, the current Linde CEO appeared to unofficially confirm speculation that the holding company will be based in Ireland with a tax domicile in the UK.

The Linde workforce has been critical of locating the holding outside Germany, thus weakening labor’s co-determination rights. But at the same time, Belloni pointed out that under the agreement Linde’s 8,000 German employees will be protected from compulsory redundancies until the end of 2021. He also rejected calls for a vote on the merger plans, saying that all Linde shareholders have the right to decide whether to tender their shares.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.